Abstract
Obesity is a risk factor for being diagnosed with asthma, but there is conflicting evidence on whether obesity is a risk factor for lung function abnormalities characteristic of asthma. We studied a cohort of 488 subjects, 47% of whom were obese. Obese and non-obese subjects with asthma had similar airflow limitation and bronchodilator responsiveness, but obese participants had increased sleep disturbance and gastroesophageal reflux disease, higher cytokine levels, and a trend towards increased exacerbations when treated with theophylline. Obese and non-obese asthmatics have similar lung function abnormalities, but comorbidities and altered responses to medications may significantly affect asthma control in obese people.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetates / pharmacokinetics
-
Acetates / therapeutic use*
-
Adult
-
Anti-Asthmatic Agents / pharmacokinetics
-
Anti-Asthmatic Agents / therapeutic use*
-
Asthma / diagnosis
-
Asthma / drug therapy*
-
Asthma / epidemiology
-
Bronchodilator Agents / pharmacokinetics
-
Bronchodilator Agents / therapeutic use*
-
Cyclopropanes
-
Cytokines / blood
-
Disease Progression
-
Double-Blind Method
-
Female
-
Forced Expiratory Volume / drug effects
-
Gastroesophageal Reflux / diagnosis
-
Gastroesophageal Reflux / epidemiology
-
Humans
-
Male
-
Middle Aged
-
Obesity / complications*
-
Obesity / epidemiology
-
Quinolines / pharmacokinetics
-
Quinolines / therapeutic use*
-
Risk Factors
-
Sleep Wake Disorders / diagnosis
-
Sleep Wake Disorders / epidemiology
-
Sulfides
-
Theophylline / pharmacokinetics
-
Theophylline / therapeutic use*
-
Treatment Outcome
-
Vital Capacity / drug effects
Substances
-
Acetates
-
Anti-Asthmatic Agents
-
Bronchodilator Agents
-
Cyclopropanes
-
Cytokines
-
Quinolines
-
Sulfides
-
Theophylline
-
montelukast